The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy. Literature review

Роль биопсии сторожевого лимфатического узла у больных раком молочной железы после неоадъювантной химиотерапии. Обзор литературы
Reshetov I.V. Khakimova G.G. Zikiryakhodzhaev A.D. Moshurova M.V. Khakimova S.G. Dzhantemirova N.M. Kazaryan L.P. Timoshkin V.O.
2024 Autonomous non-profit scientific and medical organization

Voprosy Onkologii
2024 #70 Issue 6 1040 - 1047 pp.

Sentinel lymph node biopsy (SLNB) in breast cancer (BC) is a minimally traumatic procedure that is the gold standard for the diagnosis of regional lymph node disease and an alternative to axillary lymph node dissection, avoiding complications such as shoulder contracture and arm lymphedema. This literature review analyzes the results of SLNB in patients with cN+ breast cancer status with conversion into ycN0 after neoadjuvant chemotherapy (NACT). The study analyzed publications in the databases PubMed, Scopus and Cochrane, as well as national works, for the period from January 2019 to December 2023. The incidence of false negative SLNB results in patients with cN+ status after NACT was no more than 19.3 %. Analysis of the effect of the number of sentinel lymph nodes removed on progression-free survival and relapse-free survival, provided that ycN0 is reached after NACT, did not reveal any patterns. Residual breast tumor size ≥ 5 mm and lymphovascular invasion were recognized as independent factors for non-thoracic axillary lymph node involvement, and achieving a complete pathomorphological response in the breast was a factor that increased the likelihood of achieving a complete pathomorphological response in regional lymph nodes and statistically significantly increased overall survival. The analysis of relapse-free survival in patients in the lymph node conversion group compared with the cN0 status group who underwent SLNB after NACT showed no statistically significant differences. Over a 5-year follow-up period, the incidence of locoregional recurrence was no more than 4.1 % in both cohorts. Thus, choosing SLNB after NACT improves the quality of life of BC patients without compromising OS and RFS.

breast cancer , neoadjuvant chemotherapy , sentinel lymph node biopsy

Text of the article Перейти на текст статьи

Institute of Cluster Oncology named after L.L. Levshin, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Department of Oncology, Radiotherapy and Reconstructive Surgery, Institute of Clinical Medicine named after N.V. Sklifosovsky, Moscow, Russian Federation
Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan
Department of Pediatric Oncology, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan
P.A. Herzen Moscow Research Oncology Institute, Branch of FSBI NMRRC of The Ministry of Health of Russia, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow, Russian Federation
Astana Medical University, Multidisciplinary Medical Center, Astana, Kazakhstan

Institute of Cluster Oncology named after L.L. Levshin
Department of Oncology
Republican Specialized Scientific Practical Medical Center of Oncology and Radiology
Department of Pediatric Oncology
P.A. Herzen Moscow Research Oncology Institute
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Peoples’ Friendship University of Russia named after Patrice Lumumba
Astana Medical University

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026